Global Retirement Partners LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 19.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 145,171 shares of the biopharmaceutical company’s stock after selling 35,011 shares during the period. Global Retirement Partners LLC’s holdings in Pfizer were worth $4,140,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently made changes to their positions in the business. BlackRock Inc. raised its position in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp boosted its position in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after acquiring an additional 5,501,032 shares during the last quarter. Bank of New York Mellon Corp raised its position in Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after purchasing an additional 3,999,646 shares in the last quarter. Bank of America Corp DE acquired a new position in Pfizer during the 2nd quarter valued at approximately $1,049,602,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pfizer by 4.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company’s stock worth $870,668,000 after buying an additional 1,634,374 shares during the period. 68.36% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have commented on PFE. Citigroup increased their price target on shares of Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. HSBC raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Freedom Broker increased their price objective on Pfizer from $33.00 to $34.00 and gave the company a “buy” rating in a report on Friday, November 6th. DZ Bank downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. Finally, Cantor Fitzgerald boosted their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Six equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $30.32.
Key Stories Impacting Pfizer
These are some of the PFE stories that stood out recently:
- Positive Sentiment: Pfizer’s agreement with Starna Therapeutics gives it rights outside Greater China to develop three in vivo CAR-T programs for autoimmune diseases. The deal expands Pfizer’s pipeline and could open a new avenue for growth beyond its existing products. Reuters article
- Neutral Sentiment: Pfizer reported updates on a Phase 3 study of berobenatide and a real-world study of its migraine drug Nurtec. The headlines provided no new efficacy or safety results, so the near-term investment impact is unclear. Berobenatide study article
- Negative Sentiment: The Starna deal carries up to $2.63 billion in potential payments, including $330 million upfront. Because the three programs are still pre-IND, they are years from possible commercialization and face substantial development risk; the upfront cost may help explain near-term investor caution. BioPharma Dive article
Pfizer Stock Performance
Pfizer stock opened at $27.57 on Friday. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.44. The stock’s 50 day moving average is $28.83 and its 200 day moving average is $27.02. The company has a market capitalization of $157.12 billion, a P/E ratio of 9.20, a PEG ratio of 1.84 and a beta of 0.31. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The company had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the company earned $0.87 earnings per share. The firm’s revenue was down .4% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 245.71%.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Read More
- Five stocks we like better than Pfizer
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
